Angeles Investment Advisors LLC Raises Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Angeles Investment Advisors LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 61.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,085 shares of the company’s stock after purchasing an additional 413 shares during the quarter. Angeles Investment Advisors LLC’s holdings in Eli Lilly and Company were worth $982,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. AMJ Financial Wealth Management acquired a new position in Eli Lilly and Company in the 4th quarter worth approximately $201,000. Aveo Capital Partners LLC increased its holdings in Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after buying an additional 153 shares in the last quarter. Gryphon Financial Partners LLC raised its position in shares of Eli Lilly and Company by 19.4% in the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after acquiring an additional 377 shares during the period. Main Street Financial Solutions LLC boosted its stake in shares of Eli Lilly and Company by 2.5% during the 4th quarter. Main Street Financial Solutions LLC now owns 876 shares of the company’s stock worth $511,000 after acquiring an additional 21 shares in the last quarter. Finally, Motco grew its position in shares of Eli Lilly and Company by 270.8% during the 4th quarter. Motco now owns 9,219 shares of the company’s stock valued at $5,374,000 after acquiring an additional 6,733 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on LLY. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 9th. Barclays raised their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Truist Financial reaffirmed a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Bank of America raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Jefferies Financial Group upped their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 1,441 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the transaction, the insider now owns 97,367,369 shares of the company’s stock, valued at approximately $89,093,089,982.38. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 451,900 shares of company stock valued at $418,732,178. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Down 1.2 %

NYSE LLY opened at $923.71 on Monday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $877.92 billion, a P/E ratio of 136.04, a PEG ratio of 2.79 and a beta of 0.42. The firm’s 50-day moving average is $897.12 and its two-hundred day moving average is $833.89. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th were given a dividend of $1.30 per share. The ex-dividend date was Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.